ABSTRACT
This study was designed to evaluate the safety and performance of Metafor™ SES in real-world patients with coronary artery disease. This was retrospective, single-centre, post-marketing, observational study. The primary endpoint was the occurrence of major adverse cardiac event (MACE). A total of 141 patients (187 lesions) were treated with the study device. The average stent length and diameter was 24.75 ± 9.50 mm and 2.93 ± 0.38 mm, respectively. The cumulative incidence of MACE was 1.42%. No incidence of stent thrombosis was observed at 12-months follow-up. This retrospective study demonstrated favourable safety and performance of Metafor™ SES.
Subject(s)
Absorbable Implants , Coronary Artery Disease/surgery , Drug-Eluting Stents , Percutaneous Coronary Intervention/methods , Polymers , Sirolimus/pharmacology , Female , Follow-Up Studies , Humans , Immunosuppressive Agents/pharmacology , Male , Middle Aged , Prosthesis Design , Retrospective Studies , Time Factors , Treatment OutcomeABSTRACT
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are the mainstay of therapy for cardiovascular disease and heart failure (HF). The angiotensin receptor II blocker - neprilysin inhibitor (ARNI), sacubitril-valsartan has an established role in treatment of patients with HF with reduced ejection fraction (HFrEF) based on the results of PARADIGM-HF trial. This trial has provided a strong evidence base for treatment of HFrEF in various subsets of patients. Several studies are done using ARNI in various indications such as HFrEF, HFrEF, patients hospitalized with acute decompensated HF, HF with preserved EF, AMI with LVEF <40%, hypertension, chronic kidney disease, pulmonary hypertension, obstructive sleep apnea, so on and so forth. This review provides an update of current literature and future perspective on ARNI in various cardiovascular disorders.
Subject(s)
Cardiovascular Diseases , Heart Failure , Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors , Cardiovascular Diseases/epidemiology , Heart Failure/drug therapy , Humans , Stroke VolumeABSTRACT
Hypertension is a major risk factor for cardiovascular and cerebrovascular disease. Recent studies have identified an association between low vitamin D levels and hypertension. We investigated the association between vitamin D levels and hypertension in the general population. We recruited 400 hypertensive subjects and compared them with 400 age- and sex-matched normotensive subjects. This study was carried out at Yashoda Hospital, Hyderabad, India from January 2015 to December 2017. Both groups underwent risk factor evaluation, estimation of serum 25-hydroxyvitamin D levels, and C-reactive protein (CRP) and liver function tests. Out of the 400 hypertensive subjects, 164 (40.2%) had serum 25-hydroxyvitamin D deficiency, compared with 111 (27.7%) normotensive subjects (p = 0.0001). Deficiency of serum 25-hydroxyvitamin D in hypertensive subjects was significantly associated with CRP positivity, low levels of mean serum calcium, low levels of mean serum phosphorous, high levels of mean alkaline phosphatase (p < 0.0001), and abnormal alanine transaminase (ALT) (p = 0.0015) compared with the same parameters in the normotensive subjects. After adjustment in the multiple logistic regression analysis, serum 25-hydroxyvitamin D deficiency (odds: 1.78; 95% CI: 1.31-2.41), CRP positivity (odds: 1.48; 95% CI: 1.48-2.32) and abnormal ALT (odds: 1.2; 95% CI: 0.98-1.94) were significantly associated with hypertension. Serum 25-hydroxyvitamin D deficiency was significantly associated with hypertension.
Subject(s)
Hypertension/blood , Vitamin D Deficiency/blood , Vitamin D/analogs & derivatives , Adult , Aged , Aged, 80 and over , Alkaline Phosphatase/blood , Blood Pressure/physiology , Cross-Sectional Studies , Female , Humans , Hypertension/complications , India , Male , Middle Aged , Prospective Studies , Vitamin D/blood , Vitamin D Deficiency/complicationsSubject(s)
Subclavian Artery , Thrombolytic Therapy/methods , Thrombosis/drug therapy , Tissue Plasminogen Activator/administration & dosage , Adult , Angiography , Female , Fibrinolytic Agents/administration & dosage , Humans , Injections, Intra-Arterial , Tenecteplase , Thrombosis/diagnosis , Ultrasonography, DopplerSubject(s)
Bioprosthesis/adverse effects , Heart Valve Prosthesis/adverse effects , Thrombosis/drug therapy , Thrombosis/etiology , Tissue Plasminogen Activator/administration & dosage , Adult , Aortic Valve Insufficiency/diagnostic imaging , Aortic Valve Insufficiency/therapy , Echocardiography, Doppler , Fibrinolytic Agents/administration & dosage , Follow-Up Studies , Humans , Infusions, Intravenous , Male , Prosthesis Failure , Pulse Therapy, Drug , Risk Assessment , Tenecteplase , Thrombosis/diagnostic imaging , Treatment OutcomeABSTRACT
Cellular proliferation and migration are fundamental processes that contribute to the injury response in major blood vessels. The resultant pathologies are atherosclerosis and restenosis. As we begin to understand the cellular changes associated with vascular injury, it is critical to determine whether the inhibition of growth and movement of cells in the vasculature could serve as a novel therapeutic strategy to prevent atherosclerosis and restenosis.
